City

Guayaquil (1)

Hangzhou (1)

Munich (1)

Overall Status

Available (1)

Not yet recruiting (1)

Recruiting (1)

Unknown status (1)

Phase

phase 1/phase 2 (1)

Sponsor

Ludwig-Maximilians - University of Munich (1)

Second Affiliated Hospital, School of Medicine, Zhejiang University (1)

Servier (1)

Sociedad de Lucha Contra el Cancer del Ecuador (1)

Collaborator

CyTIX.Inc (1)

Hangzhou Medical Biotechnology Co., Ltd (1)

Servier Pharmaceuticals, LLC (1)

Intervention

5-aminolevulinic acid (5-ala) gliolan® (1)

dendritic cell/tumor fusion vaccine (1)

fluorescence-guided surgery using 5-aminolevulinic acid (5-ala) (1)

interleukin-12 (1)

temozolomide (1)

vorasidenib (1)

Study Documents

Intervention Type

drug (3)

biological (1)

procedure (1)

Funder Type

Other (3)

Industry (1)

Study Type

Observational (2)

Expanded Access (1)

Interventional (1)

neoplasms, neuroepithelial

Showing 1 - 4 of 4

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

5-Aminolevulinic Acid Gliolan®: Usage Increase Proposal for

Not yet recruiting

High Grade Glioma
+10 more

5-Aminolevulinic Acid (5-ALA) Gliolan®
Fluorescence-Guided Surgery using 5-aminolevulinic acid (5-ALA)

Guayaquil, Guayas, Ecuador

Sociedad de Lucha Contra el Cáncer

Apr 28, 2023

Glioma, Recurrence, Disease Attributes Trial (Vorasidenib)

Available

Glioma
+10 more

Vorasidenib

(no location specified)

Oct 19, 2022

Glioblastoma, Glioma, Tumors, Neuroepithelial Trial in Hangzhou (Dendritic Cell/Tumor Fusion Vaccine, Interleukin-12,

Recruiting

Glioblastoma
+7 more

Dendritic Cell/Tumor Fusion Vaccine
+2 more

Hangzhou, Zhejiang, China
+1 more

Jun 7, 2020

Combined O-(2-[18F]Fluoroethyl)-L-tyrosine Positron Emission

Unknown status

Glioblastoma
+8 more

Munich, Bavaria, Germany

University of Munich, Dep. of Radiation Oncology

Dec 17, 2012